Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
作者信息
González-Martín Antonio, Pothuri Bhavana, Vergote Ignace, Graybill Whitney, Lorusso Domenica, McCormick Colleen C, Freyer Gilles, Backes Floor, Heitz Florian, Redondo Andrés, Moore Richard G, Vulsteke Christof, O'Cearbhaill Roisin E, Malinowska Izabela A, Shtessel Luda, Compton Natalie, Mirza Mansoor R, Monk Bradley J
机构信息
Medical Oncology Department, Cancer Center Clínica Universidad de Navarra, Madrid, Program in Solid Tumours, CIMA, Pamplona, & Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain.
Gynecologic Oncology Group (GOG Foundation), NYU Langone Health, Department of Obstetrics & Gynecology, Perlmutter Cancer Center, New York, NY, USA.
出版信息
Future Oncol. 2024;20(22):1531-1544. doi: 10.2217/fon-2023-0782. Epub 2024 Mar 19.
Abstract
摘要
相似文献
1
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.随访3.5年的无进展生存期和安全性：新诊断卵巢癌患者尼拉帕利维持治疗的随机3期PRIMA/ENGOT-OV26/GOG-3012试验结果——通俗易懂的总结
Future Oncol. 2024;20(22):1531-1544. doi: 10.2217/fon-2023-0782. Epub 2024 Mar 19.
2
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.尼拉帕利对比安慰剂用于治疗新诊断的晚期卵巢癌患者的健康相关生活质量：来自 III 期随机 PRIMA/ENGOT-OV26/GOG-3012 试验的结果。
Gynecol Oncol. 2024 May;184:168-177. doi: 10.1016/j.ygyno.2024.01.021. Epub 2024 Feb 6.
3
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.尼拉帕利用于新诊断的晚期卵巢癌患者的一线维持治疗：PRIMA/ENGOT-OV26/GOG-3012 试验的最终总生存结果。
Ann Oncol. 2024 Nov;35(11):981-992. doi: 10.1016/j.annonc.2024.08.2241. Epub 2024 Sep 14.
4
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.尼拉帕利用于 65 岁及以上晚期卵巢癌患者的疗效和安全性：PRIMA/ENGOT-OV26/GOG-3012 试验结果。
Gynecol Oncol. 2024 Aug;187:128-138. doi: 10.1016/j.ygyno.2024.03.009. Epub 2024 Jun 3.
5
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
6
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.PRIMA/ENGOT-OV26/GOG-3012 研究中尼拉帕利一线维持治疗的尼拉帕利个体化起始剂量的耐受性。
Eur J Cancer. 2024 Sep;208:114157. doi: 10.1016/j.ejca.2024.114157. Epub 2024 Jun 10.
7
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.比较尼拉帕利与铂类紫杉类联合化疗作为新诊断同源重组缺陷型 III/IV 期卵巢癌患者的新辅助治疗：开放标签、2 期、随机对照、多中心 OPAL 试验队列 C 的研究方案。
Trials. 2024 May 4;25(1):301. doi: 10.1186/s13063-024-08142-5.
8
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.PRIMA/ENGOT-OV26/GOG-3012 研究中尼拉帕利治疗的卵巢癌患者长期无进展生存的预测因素。
Int J Gynecol Cancer. 2024 Jul 1;34(7):1041-1050. doi: 10.1136/ijgc-2024-005356.
9
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.无进展生存期和 3.5 年随访时的安全性：尼拉帕利维持治疗新诊断卵巢癌患者的随机 3 期 PRIMA/ENGOT-OV26/GOG-3012 试验的结果。
Eur J Cancer. 2023 Aug;189:112908. doi: 10.1016/j.ejca.2023.04.024. Epub 2023 May 3.
10
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利在新诊断的晚期卵巢癌患者中的群体药代动力学和暴露-反应关系。
Clin Ther. 2024 Aug;46(8):612-621. doi: 10.1016/j.clinthera.2024.06.001. Epub 2024 Jul 16.
引用本文的文献
1
LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer.在卵巢癌中，LEF1通过上调PARP1和NUMA1赋予对DNA损伤化疗的抗性。
Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03561-3.
2
Factors Influencing Severe Hematologic Toxicity Following Niraparib Therapy in Patients With Ovarian Cancer.影响卵巢癌患者尼拉帕利治疗后严重血液学毒性的因素
Cancer Diagn Progn. 2025 May 3;5(3):378-385. doi: 10.21873/cdp.10450. eCollection 2025 May-Jun.
3
Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance.奥拉帕利与尼拉帕利安全性概况的比较研究：来自欧洲药品管理局药物警戒系统的真实世界数据分析
Pharmaceuticals (Basel). 2025 Apr 4;18(4):528. doi: 10.3390/ph18040528.
4
Assessment of safety of niraparib maintenance therapy in epithelial ovarian cancer: an updated systematic review and meta-analysis of randomized control trials.尼拉帕利维持治疗上皮性卵巢癌的安全性评估：一项随机对照试验的更新系统评价和荟萃分析
Ann Med Surg (Lond). 2025 Mar 18;87(4):2336-2345. doi: 10.1097/MS9.0000000000003186. eCollection 2025 Apr.
Zotero 插件